Linda Rogers (Icahn School of Medicine at Mount Sinai, New York, NY, US) discusses the background and findings of her presentation entitled: A Real World, Single Center Experience of Treatment of Severe Eosinophilic Asthma with IL-5 Antagonists; Mepolizumab and Reslizumab (abstract available here).
1. Why is the treatment of eosinophilic asthma so challenging? (0:12)
2. What is the rationale for using interleukin 5 (IL-5) antagonists in patients with severe eosinophilic asthma? (0:43)
3. Could you tell us about your recent study investigating mepolizumab and reslizumab? (1:33)
4. Why do you think some patients who failed to respond to mepolizumab subsequently responded to reslizumab? (2:38)
5. What further studies are needed to optimise the use of these agents? (3:14)
Speaker disclosure: Linda Rogers has nothing to disclose in relation to this video interview.
Filmed at the American Thoracic Society (ATS) International Conference 2018, San Diego, CA, US, May 2018.
Share this Video
Related Videos In Asthma
Andrew Menzies-Gow, ERS 2021: Personalised Treatment for Severe Asthma
It was a pleasure to meet with Professor Andrew Menzies-Gow (Royal Brompton Hospital and Imperial College London, London, UK) to talk around personalised treatment and emerging hot topics in severe asthma. Questions How can we further personalise treatment for people with severe asthma? (0:11) What are the hot topics and latest research you are looking […]
Andrew Menzies-Gow, ERS 2021: Benralizumab Following Oral Corticosteroid Reduction in Severe Asthma
TouchRESPIRATORY got the opportunity to catch up with Professor Andrew Menzies-Gow (Royal Brompton Hospital and Imperial College London, London, UK) to discuss oral corticosteroid (OCS) dependency in severe asthma and the use of benralizumab following OCS reduction. The abstract ‘Durable clinical benefit of benralizumab following oral corticosteroid reduction: The PONENTE study.’ (ID:1460) was presented at […]
Sarah Diver, ATS 2021: The CASCADE Study
TouchRESPIRATORY got the opportunity to catch up with Dr Sarah Diver (University of Leicester, Leicester, UK) around the CASCADE study, investigating the use of tezepelumab in patients with moderate-to-severe uncontrolled asthma. ‘Effect of tezepelumab on airway inflammatory cells, remodeling and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma: a randomized, double-blind, placebo-controlled trial’ was presented at […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!